Sistema de Salut de Catalunya
Institut Català de la Salut
[Brunet-Mas E] Gastroenterlogy Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. [Selva A] Clinical Epidemiology and Cancer Screening, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT_CERCA), Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Pediatrics, Obstetrics, Gynecology and Preventive Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain. [Bas-Cutrina F] Gastroenterology Department, Hospital General de Granollers, Granollers, Spain. [Brujats A] Gastroenterology Department, Hospital de Berga - Salut Catalunya Central, Berga, Spain. Gastroenterology Department, Hospital de la Santa Creu i Sant Pau de Barcelona, Barcelona, Spain. [Caballol B] Gastroenterology Department, Hospital Clinic i Provincial, Institut d'Investigacions biomèdiques Pi Sunyer (IDIBAPS), CIBEREHD, Barcelona, Spain. [Font R] Department of Health, Catalan Cancer Plan, Barcelona, Spain. Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. [Robles-Alonso V] Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-03-11T09:31:15Z
2025-03-11T09:31:15Z
2024
2025-02
Asymptomatic inflammatory bowel disease; Colorectal cancer; Population screening
Enfermedad inflamatoria intestinal asintomática; Cribado poblacional; Cáncer colorrectal
Malaltia inflamatòria intestinal asimptomàtica; Cribratge poblacional; Càncer colorectal
Introduction: Inflammatory bowel disease (IBD) is usually diagnosed when symptomatic. Prognosis and evolution of preclinical IBD is largely unknown. However, colorectal cancer screening programs (CRCSP) detect a subset of patients with IBD with no symptoms. The aim of this study was to describe the natural history of asymptomatic IBD diagnosed through CRCSP. Methods: An observational, longitudinal, and retrospective study was performed at 22 centers in Catalonia between January 2010 and December 2019 including patients with asymptomatic IBD detected in the CRCSP. Demographic data and IBD characteristics, evolution, and treatment were recorded. Descriptive statistics and Kaplan-Meier analysis were used for the analysis. Data were given separately for IBD, Crohn's disease (CD), ulcerative colitis (UC), and IBD unclassified (IBDU). Results: One hundred eighty-eight patients were included: 103 UC (54.8%), 60 CD (31.9%), and 25 IBDU (13.3%). Sixty-six (35.1%) were women, and the average age was 59.9 ± 5.9 years. Sixty-four patients (34.0%) developed symptoms after a median follow-up of 35.6 months. Diarrhea was the most frequent symptom for CD and IBDU (25.4% and 11.5%, respectively) and blood in stools for UC (21.4%). The median time to first symptom was 11.6 months. Treatment was prescribed in 135 patients (72.2%); mesalazine was the most prescribed drug (123 patients; 65.4%). Thirteen patients (6.9%) required biological treatment. None underwent surgery. Discussion: Around one-third of asymptomatic patients with IBD developed symptoms after a medium follow-up of 3 years. Only 6.9% required biological treatment, and none required surgery. Overall, prognosis of asymptomatic IBD seems better.
This study received a 6,000€ grant for initiation to research from the Societat Catalana de Digestologia.
Article
Published version
English
Càncer - Detecció precoç; Cribatge (Medicina); Intestins - Inflamació - Diagnòstic; Intestins - Inflamació - Prognosi; Còlon - Càncer - Diagnòstic; Recte - Càncer - Diagnòstic; DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases; Other subheadings::Other subheadings::/diagnosis; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Early Diagnosis::Early Detection of Cancer; DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Asymptomatic Diseases; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms; Other subheadings::Other subheadings::/diagnosis; ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal; Otros calificadores::Otros calificadores::/diagnóstico; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::diagnóstico precoz::detección precoz del cáncer; ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedades asintomáticas; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales; Otros calificadores::Otros calificadores::/diagnóstico
Wolters Kluwer Health
Clinical and Translational Gastroenterology;16(2)
https://doi.org/10.14309/ctg.0000000000000740
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3439]
